IO Biotech, Inc. - Common Stock, par value $0.001 per share (IOBT)
CUSIP: 449778109
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 73,755,848
- Total 13F shares
- 18,182,707
- Share change
- -928,910
- Total reported value
- $25,273,480
- Price per share
- $1.39
- Number of holders
- 26
- Value change
- -$1,285,024
- Number of buys
- 10
- Number of sells
- 9
Quarterly Holders Quick Answers
What is CUSIP 449778109?
CUSIP 449778109 identifies IOBT - IO Biotech, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 449778109:
Top shareholders of IOBT - IO Biotech, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Invest A/s Lundbeckfond |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
21,851,920
mixed-class rows
|
$14,438,960 | — | 09 Aug 2023 | |
| Vivo Capital IX, LLC |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
12,346,878
mixed-class rows
|
$9,510,598 | — | 09 Aug 2023 | |
| Vivo Capital, LLC |
13F
|
Company |
8.4%
|
6,173,439
|
$6,729,049 | — | 31 Mar 2025 | |
| Novo Holdings A/S |
3/4/5
13F
|
10%+ Owner · Company |
4.5%
from 13F
|
6,823,584
mixed-class rows
|
$5,709,989 | — | 25 Jul 2024 | |
| HBM Healthcare Investments (Cayman) Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,690,545
|
$2,784,714 | — | 09 Nov 2021 | |
| Samsara BioCapital, L.P. |
13D/G
|
— |
3.8%
|
2,631,578
|
$2,578,946 | $0 | 31 Dec 2024 | |
| PFM Health Sciences, LP |
13F
|
Company |
3.2%
|
2,341,107
|
$2,551,807 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
2.9%
|
2,105,262
|
$2,294,736 | — | 31 Mar 2025 | |
| Claus A. Andersson |
3/4/5
|
Director |
—
class O/S missing
|
1,791,490
|
$1,854,192 | — | 09 Nov 2021 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
2.2%
|
1,651,515
|
$1,800,151 | — | 31 Mar 2025 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
1.2%
|
864,197
|
$941,975 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.1%
|
789,461
|
$860,512 | — | 31 Mar 2025 | |
| Dauntless Investment Group, LLC |
13F
|
Company |
0.92%
|
681,446
|
$742,776 | — | 31 Mar 2025 | |
| Kurma Partners |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
623,428
|
$645,248 | — | 09 Aug 2023 | |
| Vanessa Malier |
3/4/5
|
Director |
—
class O/S missing
|
430,477
|
$445,544 | — | 09 Nov 2021 | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
0.54%
|
400,234
|
$436,255 | — | 31 Mar 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.26%
|
192,670
|
$210,010 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.17%
|
126,400
|
$137,776 | — | 31 Mar 2025 | |
| SECTORAL ASSET MANAGEMENT INC |
13F
|
Company |
0.13%
|
95,000
|
$103,550 | — | 31 Mar 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.1%
|
75,000
|
$81,750 | — | 31 Mar 2025 | |
| Amy Sullivan |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
299,632
mixed-class rows
|
$70,041 | — | 02 Apr 2025 | |
| Mai-Britt Zocca |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
656,471
mixed-class rows
|
$61,911 | — | 02 Apr 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.07%
|
50,486
|
$55,030 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.06%
|
45,555
|
$49,655 | — | 31 Mar 2025 | |
| Marex Group plc |
13F
|
Company |
0.06%
|
45,000
|
$49,050 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
33,307
|
$36,304 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.04%
|
30,858
|
$33,000 | — | 31 Mar 2025 | |
| Qasim Iftikhar Ahmad |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
246,350
mixed-class rows
|
$26,553 | — | 02 Apr 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.03%
|
23,717
|
$25,852 | — | 31 Mar 2025 | |
| Vontobel Holding Ltd. |
13F
|
Company |
0.03%
|
20,029
|
$21,832 | — | 31 Mar 2025 | |
| Heidi Hunter |
3/4/5
|
Director |
—
mixed-class rows
|
50,144
mixed-class rows
|
$20,884 | +$20,885 | 05 Jun 2025 | |
| Devin W. Smith |
3/4/5
|
General Counsel |
—
mixed-class rows
|
156,938
mixed-class rows
|
$13,720 | — | 02 Apr 2025 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
12,355
|
$13,467 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
130
|
$142 | — | 31 Mar 2025 | |
| Eva Ehrnrooth |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
120,000
|
— | — | 20 Mar 2023 | |
| Muhammad Al-Hajj |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
120,000
|
— | — | 20 Mar 2023 | |
| Keith A. Vendola |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
69,469
|
— | — | 04 Nov 2021 | |
| Brian Burkavage |
3/4/5
|
Chief Accounting Officer |
—
class O/S missing
|
65,000
|
— | — | 02 Apr 2025 | |
| Jack Nielsen |
3/4/5
|
Director |
—
class O/S missing
|
41,533
|
— | — | 08 Jun 2023 | |
| Christian E. Elling |
3/4/5
|
Director |
—
class O/S missing
|
35,144
|
— | — | 05 Jun 2025 | |
| David V Smith |
3/4/5
|
Director |
—
class O/S missing
|
35,144
|
— | — | 05 Jun 2025 | |
| Helen Louise Collins |
3/4/5
|
Director |
—
class O/S missing
|
35,144
|
— | — | 05 Jun 2025 | |
| Kathleen Sereda Glaub |
3/4/5
|
Director |
—
class O/S missing
|
35,144
|
— | — | 05 Jun 2025 | |
| Peter Hirth |
3/4/5
|
Director |
—
class O/S missing
|
35,144
|
— | — | 05 Jun 2025 |
Institutional Holders of IO Biotech, Inc. - Common Stock, par value $0.001 per share (IOBT) as of Q2 2025
As of 30 Jun 2025,
IO Biotech, Inc. - Common Stock, par value $0.001 per share (IOBT) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,182,707 shares.
The largest 10 holders included
Vivo Capital, LLC, NOVO HOLDINGS A/S, MARSHALL WACE, LLP, PFM Health Sciences, LP, BANK OF AMERICA CORP /DE/, Pivotal bioVenture Partners Investment Advisor LLC, MORGAN STANLEY, LANDSCAPE CAPITAL MANAGEMENT, L.L.C., Dauntless Investment Group, LLC, and Soleus Capital Management, L.P..
This page lists
26
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
21
Q2 2025 holders
26
Holder diff
5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.